[Antiestrogen therapy of patients with uterine cancer]

Review OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-10-11 ⓘ

This review discusses the pharmacological and clinical aspects of anti-estrogenic agents, including tamoxifen, aromatase inhibitors, danazol, and LHRH agonists, as adjunctive endocrine therapy for recurrent endometrial cancer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

It has been widely accepted that the estrogen is one of the contributing factors to the development of endometrial cancer of the uterus. The objective responsiveness of recurrent endometrial cancer to medroxyprogesterone acetate (MPA) has been substantiated. Many researchers have examined whether the anti-estrogenic agents could be the choice of treatment of endometrial cancer including tamoxifen (TAM), aromatase inhibitors, danazol and luteinizing releasing hormone (LHRH)-agonist as an adjunctive endocrine therapy. In this review, we discussed the pharmacological and clinical aspects of these new agents.

My notes (saved in your browser only)

MeSH descriptors

Estrogen Antagonists Uterine Neoplasms Danazol Danazol Danazol Estrogen Antagonists Estrogen Antagonists Female Humans Medroxyprogesterone Acetate Medroxyprogesterone Acetate Medroxyprogesterone Acetate Tamoxifen Tamoxifen Tamoxifen Uterine Neoplasms

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-10T11:46:18.659686+00:00
pubmed
last seen: 2026-10-08T21:59:20.378211+00:00
License: CC0 · commercial use OK